In this study, the in silico experiments demonstrated that IMPA2 downregulation may correlate with an increased activity of mTORC1 in metastatic ccRCC, and this scenario closely associates with a poorer prognosis in ccRCC patients. Here, IMPA2 is linked to nonpapillary renal cell carcinoma.